Jefferies Financial Group Inc. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Jefferies Financial Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 22,095 shares of the biopharmaceutical company’s stock, valued at approximately $6,651,000.

Other large investors have also made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $27,000. Golden State Wealth Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $237.10 on Friday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The business has a fifty day moving average of $262.62 and a 200-day moving average of $293.73. The stock has a market cap of $31.73 billion, a price-to-earnings ratio of 44.07 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter last year, the business posted ($0.51) EPS. The firm’s quarterly revenue was up 66.9% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of several research analyst reports. HC Wainwright dropped their price objective on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research report on Friday, July 31st. Stifel Nicolaus decreased their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.